Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators […]
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators […]
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease […]
Lessons in Innovation: Clark Turner’s Impact on Medical Imaging […]
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI […]
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma […]
Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems […]
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News. […]
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients. […]
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. […]
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk […]
Transforming Care for Severe AS Patients […]